Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

NCT01033721 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: Palomid 529

Sponsor

Paloma Pharmaceuticals, Inc.